Compare iShares Core US Aggregate Bond ETF (AGG) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs BioNTech SE - ADR — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.51, while BioNTech SE - ADR trades at $93.19 (market cap $23.31B). The key difference: BioNTech SE - ADR is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | BNTX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $119.34 |
52-Week Low | $97.24 | $83.89 |
Market Cap | — | $23.31B |
Enterprise Value | — | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $97.505, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights institutional activity, including Bay Colony Advisory reducing holdings and First Bank & Trust increasing its stake. Bond ETF flows remain strong, with $300 billion in H1 2026 inflows, but rising Treasury yields and inflation concerns pressure fixed-income assets.
The outlook is cautious due to bearish technicals and macroeconomic headwinds like higher yields and oil prices. Risks include Fed rate hike expectations and Middle East tensions, but AGG offers steady dividends and remains a core holding for income-focused portfolios amid market volatility.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
